Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: case report and exploration of possible mechanisms | Synapse
August 1, 2024Open Access
Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: case report and exploration of possible mechanisms
Key Points
Key points are not available for this paper at this time.
Abstract
Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with